MARKET

ALPN

ALPN

Alpine Immune Sc
NASDAQ
64.97
+0.01
+0.02%
Suspension 16:03 05/17 EDT
OPEN
64.98
PREV CLOSE
64.96
HIGH
65.00
LOW
64.97
VOLUME
4.29M
TURNOVER
0
52 WEEK HIGH
65.00
52 WEEK LOW
8.11
MARKET CAP
4.46B
P/E (TTM)
-95.0410
1D
5D
1M
3M
1Y
5Y
What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. The company is developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. 11 analysts have recently evaluated Alpine Immune sciences and provided 12-month price targets. The average price target is $ and the company's revenue growth has faced challenges.
Benzinga · 4d ago
Alpine Immune Sciences Price Target Maintained With a $65.00/Share by Wedbush
Dow Jones · 4d ago
Wedbush Reiterates Neutral on Alpine Immune Sciences, Maintains $65 Price Target
Benzinga · 4d ago
Analysts Offer Insights on Healthcare Companies: Eyenovia (EYEN), Alpine Immune Sciences (ALPN) and GoodRx Holdings (GDRX)
TipRanks · 4d ago
ALPN Factor-Based Stock Analysis
NASDAQ · 4d ago
XBI, ALPN, RVMD, IBRX: Large Outflows Detected at ETF
NASDAQ · 5d ago
Weekly Report: what happened at ALPN last week (0506-0510)?
Weekly Report · 05/13 11:45
Alpine Immune Sc: Statement of changes in beneficial ownership of securities
Press release · 05/11 00:07
More
About ALPN
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Webull offers Alpine Immune Sciences Inc stock information, including NASDAQ: ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.